子宫肌瘤是常见的女性良性肿瘤,发病率高,目前治疗方法主要以手术治疗为主,随着社会的发展,腔镜水平的进步,腹腔镜、宫腔镜手术及微无创治疗逐渐成为子宫肌瘤治疗的主要手段。近年来药物治疗、射频、聚焦超声等保留子宫、保留生育能力的治疗方法,逐渐受到关注,现就子宫肌瘤的治疗研究进展展开论述。 Hysteromyoma is a common female benign tumor with high incidence. At present, surgical is the main treatment method. With the development of society and the progress of endoscopic level, laparoscopic, hysteroscopic surgery and micro non-invasive treatment gradually become the main means of hysteromyoma treatment. In recent years, drug therapy, radiofrequency, focused ultra-sound and other treatment methods to retain the uterus and fertility have attracted more and more attention.
高逸龙,刘义彬. 子宫肌瘤治疗研究进展Progress in the Treatment of Hysteromyoma[J]. 临床医学进展, 2020, 10(03): 260-264. https://doi.org/10.12677/ACM.2020.103041
参考文献ReferencesWise, L.A., Palmer, J.R., Stewart, E.A., et al. (2005) Age-Specific Incidence Rates for Self-Reported Uterine Leiomyomata in the Black Women’s Health Study. Obstetrics & Gynecology, 105, 563-568.
<br>https://doi.org/10.1097/01.AOG.0000154161.03418.e3Toz, E., Sanci, M., Ozcan, A., et al. (2016) Compar-ison of Classic Terminology with the FIGO PALM-COEIN System for Classification of the Underlying Causes of Abnormal Uterine Bleeding. International Journal of Gynecology & Obstetrics, 133, 325-328. <br>https://doi.org/10.1016/j.ijgo.2015.09.033郎景和, 等. 子宫肌瘤的诊治中国专家共识[J]. 中华妇产科杂志, 2017, 52(12): 793-800.Donnez, J., Donnez, O. and Dolmans, M.M. (2014) With the Advent of Selective Progesterone Receptor Modulators, What Is the Place of Myoma Surgery in Current Practice? Fertility and Sterility, 102, 640-648.
<br>https://doi.org/10.1016/j.fertnstert.2014.06.041Carranza-Mamane, B., Havelock, J. and Hemmings, R. (2015) The Management of Uterine Fibroids in Women with Otherwise Unexplained Infertility. Journal of Obstetrics and Gynaecology Canada, 37, 277-285.
<br>https://doi.org/10.1016/S1701-2163(15)30318-2Tian, Y.C., Long, T.F. and Dai, Y.M. (2015) Pregnancy Outcomes Following Different Surgical Approaches of Myomectomy. Journal of Obstetrics and Gynaecology Research, 41, 350-357. <br>https://doi.org/10.1111/jog.12532Vilos, G.A., Allaire, C., Laberge, P.Y., et al. (2015) The Management of Uterine Leiomyomas. Journal of Obstetrics and Gynaecology Canada, 37, 157-1780. <br>https://doi.org/10.1016/S1701-2163(15)30338-8阳春芳. 高强度聚焦超声在子宫肌瘤治疗中的应用效果[J]. 中国妇幼保健, 2018, 33(3): 691-693.Coddington, C.C., Collins, R.L., Shawker, T.H., et al. (1986) Long-Acting Gonadotropin Hormone-Releasing Hormone Analog Used to Treat Uteri. Fertility and Sterility, 45, 624-629. <br>https://doi.org/10.1016/S0015-0282(16)49332-5Farris, M., Bastianelli, C., Rosato, E., et al. (2019) Uterine Fibroids: An Update on Current and Emerging Medical Treatment Options. Therapeutics and Clinical Risk Management, 15, 157-178. <br>https://doi.org/10.2147/TCRM.S147318Pohl, O., Marchand, L., Fawkes, N., et al. (2018) Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy with Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109. The Journal of Clinical Endocrinology & Metabolism, 103, 497-504. <br>https://doi.org/10.1210/jc.2017-01875Osuga, Y., Enya, K., Kudou, K., et al. (2019) Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared with Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial. Obstetrics & Gynecology, 133, 423-433. <br>https://doi.org/10.1097/AOG.0000000000003141Liu, C., Lu, Q., Qu, H., et al. (2017) Different Dosages of Mifepristone versus Enantone to Treat Uterine Fibroids: A Multicenter Randomized Controlled Trial. Medicine (Bal-timore), 96, e6124.
<br>https://doi.org/10.1097/MD.0000000000006124